BPG is committed to discovery and dissemination of knowledge
Randomized Clinical Trial
Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Figure 5
Figure 5 Scatter plot of incremental cost-effectiveness probability sensitivity analysis (n = 1000). The fourth quadrant indicated that the flupentixol-melitracen + lansoprazole regimen is an advantageous solution (with good performance and low cost).


Write to the Help Desk